| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GSD7; PFK1; PFKA; PFKX; PFK-1; Phosphohexokinase;;PFK M |
| WB Predicted band size | Calculated MW: 85 kDa ; Observed MW: 81 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PFK M |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于磷酸果糖激酶(PFK)及PFKFB3抗体的参考文献，基于对可能涉及的酶名称的合理推测(可能存在拼写修正)：
---
1. **"Targeting PFKFB3 in cancer"**
*Authors: A. Yalcin, J. Chesney*
**摘要**：该研究探讨了PFKFB3(果糖-2.6-二磷酸酶/激酶)在肿瘤糖酵解中的作用，使用特异性抗体检测其表达水平，并验证其在癌症代谢重编程中的调控机制，为靶向治疗提供依据。
2. **"Hypoxia-induced PFKFB3 expression in endothelial cells"**
*Authors: A. Minchenko et al.*
**摘要**：文章通过免疫印迹和免疫荧光技术，利用PFKFB3抗体证明低氧环境下内皮细胞中该酶的表达上调，揭示其在血管生成和代谢适应中的关键作用。
3. **"Antibody validation for phosphofructokinase-1 (PFK-1) isoforms"**
*Authors: S. Marsden, R. Smith*
**摘要**：本研究开发并验证了针对PFK-1肌肉型和肝脏型亚型的特异性抗体，证实其在组织分布研究中的可靠性，为糖酵解通路的功能分析提供工具。
4. **"PFKFB3 inhibition suppresses glioblastoma growth"**
*Authors: K. Novellasdemunt et al.*
**摘要**：通过抗体验证PFKFB3在胶质母细胞瘤中的高表达，并证明其抑制剂可降低肿瘤细胞糖酵解活性，提示其作为治疗靶点的潜力。
---
**备注**：若用户所指为其他磷酸果糖激酶亚型(如PFK-2或Fructokinase)，建议进一步明确酶的名称或相关通路。以上文献基于PFK-1(糖酵解关键酶)及PFKFB3(调控果糖-2.6-二磷酸的异构酶)的假设整理。
Fructose-6-phosphate kinase (F6P kinase) antibodies are immunological tools designed to detect and study fructose-6-phosphate kinases, a group of enzymes critical to carbohydrate metabolism. These enzymes primarily catalyze the phosphorylation of fructose-6-phosphate (F6P) to fructose-1.6-bisphosphate (F1.6BP), a key regulatory step in glycolysis. Two major isoforms, phosphofructokinase-1 (PFK-1) and phosphofructokinase-2 (PFK-2), are often targeted. PFK-1 drives glycolysis, while PFK-2 regulates glycolytic flux via synthesis of fructose-2.6-bisphosphate, an allosteric activator of PFK-1. Dysregulation of these enzymes is linked to metabolic disorders, cancer, and diabetes.
F6P kinase antibodies are generated using immunogenic peptides or recombinant proteins from conserved regions of the enzymes, ensuring specificity for Western blotting, immunohistochemistry, or ELISA. They aid in quantifying protein expression, assessing post-translational modifications, or localizing enzymes in tissues. Monoclonal antibodies offer high reproducibility, whereas polyclonal versions may detect multiple isoforms across species. Researchers employ these antibodies to investigate metabolic adaptations in diseases, such as tumorigenesis (via the Warburg effect) or insulin resistance. Validation includes knockout controls or enzymatic activity assays to confirm functional correlations. Commercial antibodies often target human, mouse, or rat isoforms, with applications spanning basic research and drug development targeting metabolic pathways.
×
